GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...

Investigator-sponsored study Title: “PROMise Trial: Interim analysis of PROMise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis ...

Many investors continue to be worried about Incyte’s financial prospects when the patent for the company’s blood cancer ...

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquired as part of its $1.9 ...

"The data being presented demonstrate our commitment, as well as that of our partners to our ongoing work in multiple myeloma and myelofibrosis." ...

The full blood count is the most requested haematology test. Learn how to interpret the results, including red cell and white ...

Rachael Nixon desperately needs to find a stem cell donor, after being diagnosed with a rare and aggressive form of blood cancer.

Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with ...